abstract: The lethal effects of combinations of @entity1 (ADR) and either @entity3 (HU) or @entity5 ( @entity4 ) were studied in relation to drug-scheduling interval in @entity0 cells grown in vitro. @entity2 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity4 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity4 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity4 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity4 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity4 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity3 with XXXX and @entity5 with @entity1 .

answer: @entity1


abstract: The lethal effects of combinations of @entity1 (ADR) and either @entity3 (HU) or @entity5 ( @entity4 ) were studied in relation to drug-scheduling interval in @entity0 cells grown in vitro. @entity2 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity4 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity4 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity4 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity4 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity4 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity3 with @entity1 and @entity5 with XXXX .

answer: @entity1


abstract: The lethal effects of combinations of @entity1 (ADR) and either @entity3 (HU) or @entity5 ( @entity4 ) were studied in relation to drug-scheduling interval in @entity0 cells grown in vitro. @entity2 was determined by cell cloning in soft agar. Serial kinetic changes induced by a priming dose of HU or @entity4 were monitored by flow cytometry and related to schedule-dependent cell killing by ADR. All drug exposures were for 1 hr. When ADR was given together with either HU or @entity4 , cell log kill was additive. However, when ADR was given after exposure to either HU or @entity4 , cell killing was increased up to 200- to 500-fold, respectively. Maximum schedule-dependent synergism was observed at a drug-scheduling interval of 2 hr; schedule-dependent synergism decreased as the interval between drugs was increased beyond 2 hr. Schedule-dependent synergism was not observed when the same drug combinations were given in reversed order. Drug-induced changes in the DNA histogram were not seen until 5 hr after HU exposure and 8 hr after @entity4 exposure. Thus, the schedule-dependent synergism between ADR and either HU or @entity4 cannot be explained by cell cycle blockade with synchronization of cells in S phase.

title: Schedule-dependent synergism of combinations of @entity3 with @entity1 and XXXX with @entity1 .

answer: @entity5


abstract: @entity2 does not occur only in the South West Province of Cameroon. Four foci exist in the country. They are the well known focus in the Mount Kupe area, the Mbam focus, the Nyong focus and the Ntem focus. All of them are located in the rainforest within the distribution area of Potadoma. This disease, characterized by the presence of eggs in sputum and feces, has often been confused with @entity1 . In the villages where @entity2 is diagnosed by means of parasitological techniques circulating antibodies, revealed with a P. westermani antigen (ELISA), are often found in blood specimens taken from inhabitants. Teen agers suffer the most from the disease and females more often than males. @entity0 and @entity0 are traditionally concerned with crabs fishing and they eat them after partly raw. Crabs of the genus Sudanautes contain the infective metacercariae. @entity2 is enzootic and the civet cat V. civetta seems to be the main natural definitive host in Cameroon. @entity3 given orally in a single dose of 2 mg/kg body weight showed a 100% cure rate. Side reactions are mild and transient.

title: [Epidemiologic and clinical study of paragonimosis in Cameroon. Results of XXXX treatment].

answer: @entity3


abstract: OBJECTIVE: The purpose of this work was to analyze the relationships between the expression status of Lysosomal-associated protein transmembrane-4 beta 35 ( @entity4 -35) in cancerous tissues and clinicopathological characteristics and prognosis of the @entity0 with @entity2 ( @entity2 ). METHODS: The @entity2 samples from 157 @entity0 in a discovery cohort and 148 @entity0 in a testing cohort with follow-up data were used to validate the feasibility of expression of @entity4 -35 protein in predicting @entity2 prognosis. Immunohistochemical staining was used to determine the expression of @entity4 -35 protein in precancerous @entity2 . The correlation between the expression of @entity4 -35 and clinicopathologic characteristics of @entity0 with @entity2 was analyzed using chi-square test. Univariate and multivariate analyses were performed to determine the association between @entity4 -35 expression and prognosis. RESULTS: @entity4 -35 expression was increased steadily in sequential stages of precancerous @entity3 . Positive @entity4 -35 expression was more frequently detected in @entity0 with distant @entity1 (P = 0.023) and III+IV TNM stages (P = 0.042) in the discovery cohort. Kaplan-Meier survival curves and univariate analysis showed that expression of @entity4 -35 had a significant impact on overall survival of @entity0 with @entity2 in discovery cohort (P<0.001) and testing cohort (P = 0.001). @entity4 -35 expression was an independent prognostic indicator for the overall survival of @entity0 with @entity2 in both cohorts. CONCLUSIONS: The present research demonstrated that @entity4 -35 over-expression was an independent factor in @entity2 prognosis. @entity4 gene may be a useful target of interventions slowing the progression of precancerous @entity3 and a new therapy method to improve the prognosis of @entity2 .

title: Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for XXXX .

answer: @entity2


abstract: Prazosin kinetics were studied after single doses (intravenous and oral, 0.5 mg) and after increasing multiple doses (0.5 to 5 mg three times daily) in eight @entity0 with @entity1 . After intravenous administration the kinetics could be described by a linear two-compartment open model. Terminal half-life ( @entity3 ) was about 3 hr and apparent volume of distribution ( @entity4 ) about 0.6 l/kg. After oral doses bioavailability ranged between 55% and 82%. Since total plasma clearance was low (0.14 l/kg x hr) incomplete bioavailability was the result of incomplete absorption rather than of first-pass liver metabolism. The estimated extraction ratio was about 14%. Renal clearance was negligible; only 1% to 2% of the dose was recovered unchanged in urine. Binding to plasma proteins to both albumin and alpha 1-acid glycoprotein was substantial (97%), with albumin being most important. Increasing multiple doses showed that @entity2 followed first-order kinetics with a linear correlation between dose and steady-state plasma concentration (P less than 0.001). There were substantial variations in plasma concentrations between @entity0 and there were also day-to-day variations in concentration within the same @entity0 .

title: Prazosin kinetics in XXXX .

answer: @entity1


abstract: UNASSIGNED: OBJECTIVE The authors undertook this study to validate the feasibility and safety of stereotactic radiofrequency thermocoagulation (SRT) for the surgical treatment of @entity9 ( @entity9 ). METHODS Of the 109 @entity0 who underwent SRT for @entity9 ( @entity9 ) at the authors' institution between 1997 and 2013, 16 @entity0 (9 female, 7 male) had giant HHs (maximum diameter >=  30 mm). The clinical records of these 16 @entity0 were retrospectively reviewed. RESULTS The @entity0 ' age at first SRT ranged from 1 to 22 years (median 5 years). The maximum diameter of their HHs was 30-80 mm (mean 38.5 mm). Eleven HHs had bilateral attachments to the hypothalamus. All @entity0 had @entity3 ( @entity3 ), and 12 had types of @entity3 other than @entity3 . Some of these @entity0 also had @entity4 (n = 10, 62.5%), @entity2 (n = 8, 50.0%), and precocious puberty (n = 11, 68.8%). A total of 22 SRT procedures were performed; 5 @entity0 underwent repeat SRT procedures. There was no mortality or permanent morbidity. After 17 of the 22 procedures, the @entity0 experienced transient complications, including high fever (n = 7), @entity8 (n = 3), @entity7 (n = 6), disturbance of consciousness (n = 1), @entity5 (n = 1), and epidural @entity6 (n = 1). Thirteen @entity0 (81.3%) achieved freedom from @entity3 after the final SRT procedure during a follow-up period ranging from 6 to 60 months (mean 23 months). Twelve @entity0 had nongelastic @entity3 in addition to @entity3 , and 7 (58.3%) of these 12 @entity0 experienced freedom from their nongelastic @entity3 . CONCLUSIONS SRT provided minimal invasiveness and excellent @entity3 outcomes even in @entity0 with giant HHs. Repeat SRT is safe for residual @entity3 . SRT is a feasible single surgical strategy for @entity9 regardless of the @entity1 's size or shape.

title: Stereotactic radiofrequency thermocoagulation for XXXX .

answer: @entity9


abstract: PURPOSE OF REVIEW: Transcatheter @entity4 (TAVI) is the recommended treatment for most @entity0 with @entity2 at high surgical risk. However, TAVI may be clinically futile for @entity0 who have multiple comorbidities and excessive frailty. This group benefits from transition to palliative care to maximize quality of life, improve symptoms, and ensure continuity of health services. We discuss the clinical determination of utility and futility, explore the current evidence guiding the integration of palliative care in procedure-focused cardiac programs, and outline recommendations for TAVI programs. RECENT FINDINGS: The determination of futility of treatment in elderly @entity0 with @entity2 is challenging. There is a paucity of research available to guide best practices when TAVI is not an option. Opportunities exist to build on the evidence gained in the management of end of life and @entity3 . TAVI programs and primary care providers can facilitate improved communication and processes of care to provide decision support and transition to palliative care. SUMMARY: The increased availability of transcatheter options for the management of @entity1 will increase the assessment of @entity0 with life-limiting conditions for whom treatment may not be an option. It is pivotal to bridge cardiac innovation and palliation to optimize @entity0 outcomes.

title: Transition to palliative care when transcatheter XXXX is not an option: opportunities and recommendations.

answer: @entity4


abstract: Importance: @entity3 is the most common disease of the nail in adults. International guidelines urge health care professionals to perform confirmatory diagnostic testing before initiating systemic therapy. This approach was determined to be cost-effective in studies from the late 1990s but has not been evaluated more recently. The effect of testing on the costs of @entity5 , 10%, topical solution treatment is unknown. Objective: To evaluate the cost and potential harm associated with 3 approaches to @entity3 evaluation before treatment with oral @entity4 or @entity5 , 10%. Design, Setting, and @entity0 : A decision analysis that compared the costs of 3 @entity3 management algorithms based on recently published data of test statistics, disease prevalence, and relevant costs: (1) empirical therapy without confirmatory testing, (2) pretreatment confirmatory testing with @entity2 ( @entity1 ) stain followed by periodic acid-Schiff (PAS) evaluation if @entity1 testing is negative, and (3) pretreatment testing with PAS. There was no direct @entity0 evaluation. Selection of included studies was based on outcome variables and the quality of study design. The study was conducted from April 1, 2014, to September 1, 2015. Main Outcomes and Measures: Primary outcomes included direct cost of @entity3 testing and therapy and cost to avoid harm when treating @entity0 with oral @entity4 . Results: At a disease prevalence of 75%, per- @entity0 cost savings of empirical @entity4 therapy without confirmatory testing was  47 compared with the @entity1 screening model and  135 compared with PAS testing. The cost of testing necessary to prevent a single case of clinically relevant liver toxic effects related to @entity4 at a prevalence of 75% was between  18.2 million and  43.7 million for @entity1 screening and between  37.6 million and  90.2 million for PAS testing. At a prevalence of 75%, @entity1 screening and PAS testing before treatment with @entity5 , 10%, saved  272 and  406 per @entity0 per nail, respectively. Conclusions and Relevance: These results show that empirical treatment with @entity4 for @entity0 with suspected @entity3 is more cost-effective than confirmatory testing across all prevalence of disease, with minimal effect on @entity0 safety. In contrast, confirmatory testing before treatment with @entity5 , 10%, is associated with reduced costs. Blanket recommendations for confirmatory testing before systemic therapy should be reconsidered and replaced with recommendations tailored to specific therapies.

title: Cost-effectiveness of Confirmatory Testing Before Treatment of XXXX .

answer: @entity3


abstract: BACKGROUND/OBJECTIVES: The purpose of this observational study was to provide an impression of the outcomes of prehospital thrombolysis in combination with an active coronary angioplasty intervention (PCI) strategy for acute ST-elevation @entity2 . METHODS: In a group of 151 consecutive @entity0 the following parameters were measured: time delay, percentage of reperfusion, reocclusion, @entity1 , death, need for PCI and the number of protocol violations. RESULTS: The diagnosis by the ambulance paramedics was made in 8  6 minutes, followed by thrombolysis in 13  7 minutes (median  SD). In 2% (3) of the @entity0 the thrombolytic agent was erroneously administered without complications. The elapsed time from onset of symptoms to treatment was a median of 112  77 minutes. Five percent (7) of the @entity0 died in the first 30 days and 2% (3) suffered an @entity3 . Reperfusion was documented in 76% (112) of the @entity0 , from which 18% (20) reoccluded in the following 24 hours. In @entity0 where reperfusion was not established or reocclusion occurred, @entity0 underwent rescue/facilitated PCI: in total 37% (55 @entity0 ). After three months 9% (13) of the @entity0 had severly impaired (EF <40%) left ventricular function. CONCLUSION: In our region, we successfully implemented the prehospital thrombolysis system achieving a competitive call-to-needle time and reperfusion rate. The percentage of @entity0 who violated the protocol, suffered an @entity3 , died and/or had severely impaired left ventricular function was acceptable.

title: Safety and feasibility of prehospital thrombolysis in combination with active rescue PCI strategy for acute ST-elevation XXXX .

answer: @entity2


abstract: BACKGROUND: @entity3 , although benign, may produce symptoms related to @entity7 or mechanical obstruction. Surgical excision is the therapy of choice for symptomatic @entity10 in infancy. @entity0 AND METHODS: Two @entity0 with @entity10 producing symptoms underwent radiofrequency catheter ablation of the @entity1 . In @entity0 1 the diagnosis of multiple @entity10 associated with recurrent @entity11 was made in utero. After birth, several antiarrhythmic agents were administered, without successful suppression of the @entity5 . At seven months of age, the @entity0 had one large @entity1 on the left atrial aspect of the anterior mitral valve leaflet with associated @entity9 and re-entrant supraventricular @entity5 suggestive of a left-sided pathway. Catheter ablation of the accessory pathway was performed via a retrograde femoral arterial approach, targeting the earliest site of ventricular activation. @entity0 2 presented as a neonate with multiple @entity10 , one of which, measuring 15 mm * 15 mm, was producing severe mitral @entity4 resulting in symptoms of @entity6 due to a large left-to-right shunt at atrial level and persistent @entity2 . Via the femoral vein, a 5F ablation catheter was advanced across the @entity8 , and the @entity1 directly ablated. RESULTS: Echocardiography performed 24 hours later demonstrated alteration in @entity1 morphology, with the development of a large central echolucent area, followed by progressive @entity1 shrinkage in both @entity0 . @entity0 1 was discharged at 24 hours, and @entity0 2 at seven days post-ablation, without symptoms. Follow-up at four weeks confirmed further @entity1 shrinkage. CONCLUSION: Transcatheter @entity1 ablation may be beneficial in selected @entity0 and @entity0 .

title: XXXX producing symptoms in infancy: the role of radiofrequency catheter ablation.

answer: @entity10


abstract: UNASSIGNED: In the classical form of a1-antitrypsin deficiency (ATD), aberrant intracellular accumulation of misfolded mutant a1-antitrypsin Z (ATZ) in hepatocytes causes @entity2 by a gain-of-function, "proteotoxic" mechanism. Whereas some ATD @entity0 develop @entity3 ( @entity3 ) that necessitates liver transplantation, others with the same @entity1 completely escape this clinical phenotype. We investigated whether induced pluripotent stem cells (iPSCs) from ATD individuals with or without @entity3 could model these personalized variations in @entity2 phenotypes. @entity0 -specific iPSCs were generated from ATD @entity0 and a control and differentiated into hepatocyte-like cells (iHeps) having many characteristics of hepatocytes. Pulse-chase and endoglycosidase H analysis demonstrate that the iHeps recapitulate the abnormal accumulation and processing of the ATZ molecule, compared to the wild-type AT molecule. Measurements of the fate of intracellular ATZ show a marked delay in the rate of ATZ degradation in iHeps from @entity3 @entity0 , compared to those from no @entity3 @entity0 . Transmission electron microscopy showed dilated rough endoplasmic reticulum in iHeps from all individuals with ATD, not in controls, but globular inclusions that are partially covered with ribosomes were observed only in iHeps from individuals with @entity3 . CONCLUSION: These results provide definitive validation that iHeps model the individual disease phenotypes of ATD @entity0 with more rapid degradation of misfolded ATZ and lack of globular inclusions in cells from @entity0 who have escaped @entity3 . The results support the concept that "proteostasis" mechanisms, such as intracellular degradation pathways, play a role in observed variations in clinical phenotype and show that iPSCs can potentially be used to facilitate predictions of disease susceptibility for more precise and timely application of therapeutic strategies. (Hepatology 2015).

title: Induced pluripotent stem cells model personalized variations in XXXX resulting from a1-antitrypsin deficiency.

answer: @entity3


abstract: BACKGROUND: @entity4 is a @entity2 with a relatively good prognosis. The incidence of all @entity4 is approximately 9/100,000 @entity0 . There are nearly 15,000 newly diagnosed @entity0 every year ( @entity0 twice as often as @entity0 ). TREND: In the last decade, a trend away from radical open resection towards nephron-sparing approaches has been observed. Currently, partial nephrectomy is the surgical gold standard for the treatment of small @entity3 . However, excellent clinical results are obtained using percutaneous radiofrequency ablation (RFA): low complication rates and preservation of the renal function. RESULTS: Primary and secondary technical success rates are 69-100% and 90-100%, respectively. In large series, major complication rates of RFA of 0-14% are reported. A relevant deterioration of renal function after RFA is very rare. The 5-year local recurrence-free survival rates, @entity1 -free survival rates, @entity2 -specific survival rates, and overall survival rates are 88-93, 95-100, 98-100, and 58.3-85%, respectively. In this context, the lack of appropriate long-term data is often cited as a limitation. CONCLUSION: Different meta-analyses come to the conclusion that in case of adequate @entity2 and @entity0 selection RFA shows oncologic results comparable with surgical resection. Accepted indications for RFA are T1  @entity3 in @entity0 with advanced age, significant comorbidities, reduced renal function, single kidney, and/or no wish for operation. Predictors for the success include @entity2 size and location as well as operator experience. To define the real efficacy of RFA in the treatment of @entity3 , randomized controlled clinical long-term studies are indicated.

title: [Percutaneous radiofrequency ablation of XXXX : Update 2015].

answer: @entity3


abstract: In order to ascertain the therapeutic effects of @entity12 ( @entity13 ), a new semisynthetic @entity16 antibiotic, it was administered to pediatric @entity0 with several infections. There were 8 @entity0 with @entity11 ( @entity11 ), 3 with @entity2 ( @entity2 ), 2 with @entity7 complicated with @entity4 , 2 with @entity17 , one each of left coxitis, infected medial cervical cyst, @entity1 after a V-P shunt operation, purulent @entity15 and intractable @entity3 with @entity1 , namely, a total of 20 @entity0 aged from one month to 11 years 6 months. A @entity13 vial which contained 1 g of @entity13 was used in two ways, i.e., one shot intravenous injection and drip infusion. The dosage of the drug varied from 57 to 121 mg/kg/day and the administration was continued from 2 to 20 days. Clinical effects were evaluated as follows: when cardinal symptoms disappeared within 3 days it was considered to be 'excellent'; within 5 days 'good'; and no change of clinical symptoms within 5 days 'poor'. The bacteriological effect was expressed as 'eliminated', 'unchanged' and 'undetermined'. Clinical efficacy evaluated as 'excellent' occurred in 11 cases, 'good' in 8 cases and 'poor' in 1 case, the efficacy rate being 95.0%. When classified by the disease, the efficacy rate was as follows: 'good' to 'excellent' in 7 out of the 8 cases of @entity11 , 'excellent' in all of the 3 cases of @entity2 , 'good' and 'excellent' in the 2 cases of @entity17 and in the 2 cases of @entity4 , 'excellent' in each case of left coxitis, purulent @entity15 and intractable @entity3 with @entity1 , 'good' in each case of infected medial cervical cyst and @entity1 with a V-P shunt operation. From the bacteriological point of view, 'eliminated' occurred in 5 cases, 'reduced' in 1 case and 'undetermined' in the 2 cases of @entity11 , 'eliminated' in all of the 3 cases of @entity2 , 'eliminated' in 1 case and 'undetermined' in the 1 case of @entity4 , 'undetermined' in the 2 cases of @entity17 , 'eliminated' in each case of infected medial cervical cyst and purulent @entity15 and 'undetermined' in the other cases. Antimicrobial efficacy measured by MIC was compared with CEZ and CET, and the results were as follows: @entity13 was inferior to the two cephalosporins for @entity8 , it was between CEZ and CET for @entity5 and @entity14 , and @entity13 was superior to CEZ and CET for @entity6 . All of the 3 antibiotics had poor antimicrobial efficacy for @entity9 and @entity10 . There were neither clinical side effects nor abnormal laboratory findings which were obviously attributable to @entity13 during and after administration of the drug.

title: [Therapeutic effects of XXXX in the treatment of various infections in @entity0 (author's transl)].

answer: @entity12


abstract: In order to ascertain the therapeutic effects of @entity12 ( @entity13 ), a new semisynthetic @entity16 antibiotic, it was administered to pediatric @entity0 with several infections. There were 8 @entity0 with @entity11 ( @entity11 ), 3 with @entity2 ( @entity2 ), 2 with @entity7 complicated with @entity4 , 2 with @entity17 , one each of left coxitis, infected medial cervical cyst, @entity1 after a V-P shunt operation, purulent @entity15 and intractable @entity3 with @entity1 , namely, a total of 20 @entity0 aged from one month to 11 years 6 months. A @entity13 vial which contained 1 g of @entity13 was used in two ways, i.e., one shot intravenous injection and drip infusion. The dosage of the drug varied from 57 to 121 mg/kg/day and the administration was continued from 2 to 20 days. Clinical effects were evaluated as follows: when cardinal symptoms disappeared within 3 days it was considered to be 'excellent'; within 5 days 'good'; and no change of clinical symptoms within 5 days 'poor'. The bacteriological effect was expressed as 'eliminated', 'unchanged' and 'undetermined'. Clinical efficacy evaluated as 'excellent' occurred in 11 cases, 'good' in 8 cases and 'poor' in 1 case, the efficacy rate being 95.0%. When classified by the disease, the efficacy rate was as follows: 'good' to 'excellent' in 7 out of the 8 cases of @entity11 , 'excellent' in all of the 3 cases of @entity2 , 'good' and 'excellent' in the 2 cases of @entity17 and in the 2 cases of @entity4 , 'excellent' in each case of left coxitis, purulent @entity15 and intractable @entity3 with @entity1 , 'good' in each case of infected medial cervical cyst and @entity1 with a V-P shunt operation. From the bacteriological point of view, 'eliminated' occurred in 5 cases, 'reduced' in 1 case and 'undetermined' in the 2 cases of @entity11 , 'eliminated' in all of the 3 cases of @entity2 , 'eliminated' in 1 case and 'undetermined' in the 1 case of @entity4 , 'undetermined' in the 2 cases of @entity17 , 'eliminated' in each case of infected medial cervical cyst and purulent @entity15 and 'undetermined' in the other cases. Antimicrobial efficacy measured by MIC was compared with CEZ and CET, and the results were as follows: @entity13 was inferior to the two cephalosporins for @entity8 , it was between CEZ and CET for @entity5 and @entity14 , and @entity13 was superior to CEZ and CET for @entity6 . All of the 3 antibiotics had poor antimicrobial efficacy for @entity9 and @entity10 . There were neither clinical side effects nor abnormal laboratory findings which were obviously attributable to @entity13 during and after administration of the drug.

title: [Therapeutic effects of @entity12 in the treatment of various infections in XXXX (author's transl)].

answer: @entity0


abstract: BACKGROUND AND OBJECTIVE: Various nonpharmacologic treatments are available for pediatric @entity4 -related functional @entity3 (AP-FGIDs). Data on efficacy and safety are scarce. The goal of this study was to summarize the evidence regarding nonpharmacologic interventions for pediatric AP-FGIDs: lifestyle interventions, dietary interventions, behavioral interventions, prebiotics and probiotics, and alternative medicine. METHODS: Searches were conducted of the Medline and Cochrane Library databases. Systematic reviews and randomized controlled trials (RCTs) concerning nonpharmacologic therapies in @entity0 (aged 3-18 years) with AP-FGIDs were included, and data were extracted on @entity0 , interventions, and outcomes. The quality of evidence was assessed by using the GRADE approach. RESULTS: Twenty-four RCTs were found that included 1390 @entity0 . Significant improvement of @entity4 was reported after hypnotherapy compared with standard care/wait-list approaches and after cognitive behavioral therapy compared with a variety of control treatments/wait-list approaches. Written self-disclosure improved @entity2 frequency at the 6-month follow-up only. Compared with placebo, @entity7 (LGG) and VSL#3 were associated with significantly more treatment responders (LGG relative risk: 1.31 [95% confidence interval: 1.08 to 1.59]; VSL#3: P < .05). Guar gum significantly improved @entity6 symptom frequency; however, no effect was found for other fiber supplements (relative risk: 1.17 [95% confidence interval: 0.75 to 1.81]) or a @entity5 -free diet. Functional disability was not significantly decreased after yoga compared with a wait-list approach. No studies were found concerning lifestyle interventions; gluten-, @entity1 -, or @entity8 -free diets; fluid intake; or prebiotics. No serious adverse effects were reported. The quality of evidence was found to be very low to moderate. CONCLUSIONS: Although high-quality studies are lacking, some evidence shows efficacy of hypnotherapy, cognitive behavioral therapy, and probiotics (LGG and VSL#3) in pediatric AP-FGIDs. Data on fiber supplements are inconclusive.

title: Nonpharmacologic Treatment of Functional XXXX : A Systematic Review.

answer: @entity4


abstract: AIM: The aim of the present study was to investigate the prognostic @entity2 (CNS) after acquired resistance to @entity4 ( @entity4 )- @entity5 kinase inhibitor (TKI) in @entity4 -mutant @entity6 ( @entity6 ). @entity0 AND METHODS: We defined CNS-collapse as @entity3 due to uncontrolled and progressive CNS @entity1 . Post-progression survival (PPS) after initial TKI failure and @entity8 status were retrospectively compared in 92 @entity0 with or without CNS collapse. RESULTS: The median PPS in 32 @entity0 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity8 was detected in four (12%) out of the 32 CNS-collapse @entity0 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity0 with leptomeningeal @entity1 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity0 with brain @entity1 and 11.2 months in 52 without (p=0.0387). @entity8 was detected in 4/5 resected @entity7 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity8 -negative status and LM. Controlling CNS @entity1 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity1 After Acquired Resistance to XXXX -TKI: Poorer Prognosis Associated with @entity8 -negative Status and @entity1 .

answer: @entity4


abstract: AIM: The aim of the present study was to investigate the prognostic @entity2 (CNS) after acquired resistance to @entity4 ( @entity4 )- @entity5 kinase inhibitor (TKI) in @entity4 -mutant @entity6 ( @entity6 ). @entity0 AND METHODS: We defined CNS-collapse as @entity3 due to uncontrolled and progressive CNS @entity1 . Post-progression survival (PPS) after initial TKI failure and @entity8 status were retrospectively compared in 92 @entity0 with or without CNS collapse. RESULTS: The median PPS in 32 @entity0 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity8 was detected in four (12%) out of the 32 CNS-collapse @entity0 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity0 with leptomeningeal @entity1 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity0 with brain @entity1 and 11.2 months in 52 without (p=0.0387). @entity8 was detected in 4/5 resected @entity7 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity8 -negative status and LM. Controlling CNS @entity1 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System XXXX After Acquired Resistance to @entity4 -TKI: Poorer Prognosis Associated with @entity8 -negative Status and @entity1 .

answer: @entity1


abstract: AIM: The aim of the present study was to investigate the prognostic @entity2 (CNS) after acquired resistance to @entity4 ( @entity4 )- @entity5 kinase inhibitor (TKI) in @entity4 -mutant @entity6 ( @entity6 ). @entity0 AND METHODS: We defined CNS-collapse as @entity3 due to uncontrolled and progressive CNS @entity1 . Post-progression survival (PPS) after initial TKI failure and @entity8 status were retrospectively compared in 92 @entity0 with or without CNS collapse. RESULTS: The median PPS in 32 @entity0 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity8 was detected in four (12%) out of the 32 CNS-collapse @entity0 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity0 with leptomeningeal @entity1 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity0 with brain @entity1 and 11.2 months in 52 without (p=0.0387). @entity8 was detected in 4/5 resected @entity7 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity8 -negative status and LM. Controlling CNS @entity1 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity1 After Acquired Resistance to @entity4 -TKI: Poorer Prognosis Associated with @entity8 -negative Status and XXXX .

answer: @entity1


abstract: AIM: The aim of the present study was to investigate the prognostic @entity2 (CNS) after acquired resistance to @entity4 ( @entity4 )- @entity5 kinase inhibitor (TKI) in @entity4 -mutant @entity6 ( @entity6 ). @entity0 AND METHODS: We defined CNS-collapse as @entity3 due to uncontrolled and progressive CNS @entity1 . Post-progression survival (PPS) after initial TKI failure and @entity8 status were retrospectively compared in 92 @entity0 with or without CNS collapse. RESULTS: The median PPS in 32 @entity0 with CNS-collapse (16.7 months) was significantly shorter than that of 60 without (26.8 months) (p=0.0002). @entity8 was detected in four (12%) out of the 32 CNS-collapse @entity0 and in 26 (43%) out of 60 without (p=0.0026). Median PPS in 39 @entity0 with leptomeningeal @entity1 (LM) (11.4 months) was significantly shorter versus 53 without (26.8 months) (p=0.0006). The median PPS was 25.1 months in 40 @entity0 with brain @entity1 and 11.2 months in 52 without (p=0.0387). @entity8 was detected in 4/5 resected @entity7 (80%) and in 1/26 cerebrospinal fluid (CSF) samples (4%) (p=0.0008). CONCLUSION: CNS-collapse represented poorer prognosis, which was associated with @entity8 -negative status and LM. Controlling CNS @entity1 , especially LM, is important to achieve longer survival.

title: Prognostic Impact of Central Nervous System @entity1 After Acquired Resistance to @entity4 -TKI: Poorer Prognosis Associated with XXXX -negative Status and @entity1 .

answer: @entity8


abstract: UNASSIGNED: The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of @entity1 or @entity1 . In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 ( @entity5 ) antibody (Ab), @entity6 Ab and @entity7 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation @entity0 model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 @entity0 at day 28 after skin transplantation. The @entity0 were divided into four groups: i) Control (normal saline), ii) @entity5 Ab and @entity6 Ab [150  g; once daily (qd); intraperitoneal (ip)], iii) @entity7 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of @entity4 was significantly lower and the levels of @entity3 and @entity2 ( @entity2 ) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of @entity4 and interferon-y (IFN-y) were significantly lower (P<0.001) and the concentration of @entity3 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with @entity5 Ab and @entity6 Ab or @entity7 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of @entity5 Ab, @entity6 Ab and @entity7 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

title: Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with XXXX prolongs the survival of cardiac retransplantation allografts in a @entity0 model.

answer: @entity7


abstract: UNASSIGNED: The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of @entity1 or @entity1 . In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 ( @entity5 ) antibody (Ab), @entity6 Ab and @entity7 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation @entity0 model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 @entity0 at day 28 after skin transplantation. The @entity0 were divided into four groups: i) Control (normal saline), ii) @entity5 Ab and @entity6 Ab [150  g; once daily (qd); intraperitoneal (ip)], iii) @entity7 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of @entity4 was significantly lower and the levels of @entity3 and @entity2 ( @entity2 ) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of @entity4 and interferon-y (IFN-y) were significantly lower (P<0.001) and the concentration of @entity3 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with @entity5 Ab and @entity6 Ab or @entity7 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of @entity5 Ab, @entity6 Ab and @entity7 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

title: Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with @entity7 prolongs the survival of cardiac retransplantation allografts in a XXXX model.

answer: @entity0


abstract: UNASSIGNED: The aim of the present study was to assess the effectiveness and safety of endovascular interventional therapy, which is mechanical clot disruption combined with intrasinus thrombolytic therapy with recombinant @entity6 (rt-PA), for severe @entity1 ( @entity1 ). The records of eight @entity0 with @entity1 confirmed by computed tomography, magnetic resonance imaging (MRI), magnetic resonance venography (MRV) and/or digital subtraction angiography were analyzed. Of the eight cases, the Glasgow @entity3 Scale (GCS) scores were between 4 and 9 with a mean value of 8.3  2.7. All the @entity0 had @entity5 and two cases had @entity4 . Mechanical clot destruction combined with intrasinus thrombolytic therapy with rt-PA was performed under general anesthesia. Intravenous heparin therapy and intracerebral pressure control were applied during this period. One @entity0 succumbed and the other seven @entity0 showed good treatment efficacy. The GCS scores of the seven @entity0 reverted to 15 upon discharge from the Northern Jiangsu @entity0 's Hospital (Yangzhou, China). With regard to the modified Rankin score of the seven @entity0 three months following surgery, six @entity0 scored 0 and one @entity0 scored 1. MRI and MRV follow-up examinations were performed for 3-15 months. Complete recanalization of the criminal sinus, which refer to the sinus attributable to the @entity5 or @entity2 , was observed in five cases and partial recanalization was observed in two cases. Symptoms were monitored for 3-24 months and no recurrence was observed. Therefore, mechanical thrombectomy combined with intrasinus thrombolytic therapy with rt-PA is safe and effective for @entity0 with severe @entity1 .

title: Mechanical thrombectomy combined with recombinant @entity6 thrombolysis in the venous sinus for the treatment of severe XXXX .

answer: @entity1


abstract: UNASSIGNED: The aim of the present study was to assess the effectiveness and safety of endovascular interventional therapy, which is mechanical clot disruption combined with intrasinus thrombolytic therapy with recombinant @entity6 (rt-PA), for severe @entity1 ( @entity1 ). The records of eight @entity0 with @entity1 confirmed by computed tomography, magnetic resonance imaging (MRI), magnetic resonance venography (MRV) and/or digital subtraction angiography were analyzed. Of the eight cases, the Glasgow @entity3 Scale (GCS) scores were between 4 and 9 with a mean value of 8.3  2.7. All the @entity0 had @entity5 and two cases had @entity4 . Mechanical clot destruction combined with intrasinus thrombolytic therapy with rt-PA was performed under general anesthesia. Intravenous heparin therapy and intracerebral pressure control were applied during this period. One @entity0 succumbed and the other seven @entity0 showed good treatment efficacy. The GCS scores of the seven @entity0 reverted to 15 upon discharge from the Northern Jiangsu @entity0 's Hospital (Yangzhou, China). With regard to the modified Rankin score of the seven @entity0 three months following surgery, six @entity0 scored 0 and one @entity0 scored 1. MRI and MRV follow-up examinations were performed for 3-15 months. Complete recanalization of the criminal sinus, which refer to the sinus attributable to the @entity5 or @entity2 , was observed in five cases and partial recanalization was observed in two cases. Symptoms were monitored for 3-24 months and no recurrence was observed. Therefore, mechanical thrombectomy combined with intrasinus thrombolytic therapy with rt-PA is safe and effective for @entity0 with severe @entity1 .

title: Mechanical thrombectomy combined with recombinant XXXX thrombolysis in the venous sinus for the treatment of severe @entity1 .

answer: @entity6


abstract: Outpatient ambulatory EEG is more cost-effective than inpatient EEG telemetry and may provide adequate @entity2 localization in a presurgical evaluation. A 51-year-old right-handed male had been unable to work or drive since the age of 35 due to intractable partial onset @entity1 . A 72-hour outpatient ambulatory EEG recorded 18 @entity2 from the right temporal region. No @entity1 was seen in the left hemisphere. Magnetic resonance imaging showed right mesial @entity3 as well as an area of @entity4 at the medial inferior right temporal lobe. Neuropsychological assessment found that the @entity0 was a good neurosurgery candidate. At this point, the @entity0 was considered to be a candidate for a right temporal lobectomy. A standard right temporal lobectomy was performed. The @entity0 has been @entity2 -free for 10  months after the surgery. Follow-up EEGs show no @entity1 . The @entity0 is preparing to go back to work, and his driver's license was reinstated 9  months postsurgery. Neuropsychological reassessment is pending, but no apparent change in cognition has been noticed by the @entity0 or his family. Cases with a high congruence between diagnostic imaging and the EEG abnormalities identified in the portable EEG may provide enough information regarding @entity2 frequency and localization to eliminate the need for inpatient EEG telemetry in the evaluation of @entity0 for @entity1 surgery. We believe that the use of aEEG in preoperative planning should be restricted to cases of TLE and to @entity0 with a high frequency of @entity2 .

title: Outpatient ambulatory EEG as an option for XXXX surgery evaluation instead of inpatient EEG telemetry.

answer: @entity1


abstract: INTRODUCTION: The purpose of this study was to determine the proportion of symptomatic recurrence following initial non-operative management of @entity6 in the elderly and to test possible predictors. METHODS: This is a single institution retrospective chart review of @entity0  65 years and older with an initial hospital visit (V1) for symptomatic @entity6 , over a 4-year period. @entity0 with initial "non-operative" management were defined as those without surgery @entity7 and without elective surgery at visit 2 (V2). Baseline characteristics included age, sex, Charlson comorbidity index (CCI), diagnosis, and interventions (ERCP or cholecystostomy) @entity7 . Outcomes assessed over 1  year were as follows: recurrence (any ER/admission visit following V1), surgery, complications, and mortality. A survival analysis using a Cox proportional hazards model was performed to assess predictors of recurrence. RESULTS: There were 195 @entity0 initially treated non-operatively @entity7 . Mean age was 78.3      7.8  years, 45.6  % were male, and the mean CCI was 2.1      1.9. @entity7 , 54.4  % had a diagnosis of @entity1 or @entity4 , while 45.6  % had a diagnosis of @entity2 , @entity3 , or @entity5 . 39.5  % underwent ERCP or cholecystostomy. Excluding 10 @entity0 who died @entity7 , 31.3  % of @entity0 had a recurrence over the study period. Among these, 43.5  % had emergency surgery, 34.8  % had complications, and 4.3  % died. Median time to first recurrence was 2  months (range 6  days-4.8  months). Intervention @entity7 was associated with a lower probability of recurrence (HR 0.3, CI [0.14-0.65]). CONCLUSION: One-third of elderly @entity0 will develop a recurrence following non-operative management of symptomatic @entity1 . These recurrences are associated with significant rates of emergency surgery and morbidity. Percutaneous or endoscopic therapies may decrease the risk of recurrence.

title: Recurrence of XXXX following non-operative management in elderly @entity0 .

answer: @entity1


abstract: INTRODUCTION: The purpose of this study was to determine the proportion of symptomatic recurrence following initial non-operative management of @entity6 in the elderly and to test possible predictors. METHODS: This is a single institution retrospective chart review of @entity0  65 years and older with an initial hospital visit (V1) for symptomatic @entity6 , over a 4-year period. @entity0 with initial "non-operative" management were defined as those without surgery @entity7 and without elective surgery at visit 2 (V2). Baseline characteristics included age, sex, Charlson comorbidity index (CCI), diagnosis, and interventions (ERCP or cholecystostomy) @entity7 . Outcomes assessed over 1  year were as follows: recurrence (any ER/admission visit following V1), surgery, complications, and mortality. A survival analysis using a Cox proportional hazards model was performed to assess predictors of recurrence. RESULTS: There were 195 @entity0 initially treated non-operatively @entity7 . Mean age was 78.3      7.8  years, 45.6  % were male, and the mean CCI was 2.1      1.9. @entity7 , 54.4  % had a diagnosis of @entity1 or @entity4 , while 45.6  % had a diagnosis of @entity2 , @entity3 , or @entity5 . 39.5  % underwent ERCP or cholecystostomy. Excluding 10 @entity0 who died @entity7 , 31.3  % of @entity0 had a recurrence over the study period. Among these, 43.5  % had emergency surgery, 34.8  % had complications, and 4.3  % died. Median time to first recurrence was 2  months (range 6  days-4.8  months). Intervention @entity7 was associated with a lower probability of recurrence (HR 0.3, CI [0.14-0.65]). CONCLUSION: One-third of elderly @entity0 will develop a recurrence following non-operative management of symptomatic @entity1 . These recurrences are associated with significant rates of emergency surgery and morbidity. Percutaneous or endoscopic therapies may decrease the risk of recurrence.

title: Recurrence of @entity1 following non-operative management in elderly XXXX .

answer: @entity0


abstract: BACKGROUND: The aim of the present study was to investigate the efficacy of intracorporeal reinforcing sutures for preventing @entity2 ( @entity2 ) after laparoscopic surgery for @entity1 . METHODS: This was a retrospective single-institution study consisting of 201 consecutive @entity0 who underwent laparoscopic proctectomy with double-stapling anastomosis for primary @entity1 between August 2007 and December 2013. The data for @entity0 who received intracorporeal reinforcing sutures were compared with those of @entity0 who did not receive reinforcing sutures. @entity0 -, @entity1 - and surgery-related variables were collected and examined using univariate and multivariate analyses. RESULTS: The overall incidence of @entity2 was 9.0  % (18/201). No significant correlations were observed between the various clinicopathological factors and the use of reinforcing sutures. The multivariate analyses revealed the distance of the @entity1 from the anal verge, @entity1 size and presence of reinforcing sutures to be independent risk factors for @entity2 . We classified the @entity0 into two risk groups using a combination of the @entity1 site and @entity1 size: a low-risk group ( @entity0 without any risk factors, n  =  134) and a high-risk group ( @entity0 with one or two risk factors, n  =  67). The frequency of @entity2 was significantly lower (p  <  0.02) in the @entity0 treated with reinforcing sutures than in those treated without reinforcing sutures in the high-risk group. However, no significant differences were observed in the low-risk group. CONCLUSIONS: The use of intracorporeal reinforcing sutures may reduce the incidence of @entity2 . A prospective randomized trial is required to evaluate the effects of reinforcing sutures in preventing @entity2 .

title: Efficacy of intracorporeal reinforcing sutures for XXXX after laparoscopic surgery for @entity1 .

answer: @entity2


abstract: BACKGROUND: The aim of the present study was to investigate the efficacy of intracorporeal reinforcing sutures for preventing @entity2 ( @entity2 ) after laparoscopic surgery for @entity1 . METHODS: This was a retrospective single-institution study consisting of 201 consecutive @entity0 who underwent laparoscopic proctectomy with double-stapling anastomosis for primary @entity1 between August 2007 and December 2013. The data for @entity0 who received intracorporeal reinforcing sutures were compared with those of @entity0 who did not receive reinforcing sutures. @entity0 -, @entity1 - and surgery-related variables were collected and examined using univariate and multivariate analyses. RESULTS: The overall incidence of @entity2 was 9.0  % (18/201). No significant correlations were observed between the various clinicopathological factors and the use of reinforcing sutures. The multivariate analyses revealed the distance of the @entity1 from the anal verge, @entity1 size and presence of reinforcing sutures to be independent risk factors for @entity2 . We classified the @entity0 into two risk groups using a combination of the @entity1 site and @entity1 size: a low-risk group ( @entity0 without any risk factors, n  =  134) and a high-risk group ( @entity0 with one or two risk factors, n  =  67). The frequency of @entity2 was significantly lower (p  <  0.02) in the @entity0 treated with reinforcing sutures than in those treated without reinforcing sutures in the high-risk group. However, no significant differences were observed in the low-risk group. CONCLUSIONS: The use of intracorporeal reinforcing sutures may reduce the incidence of @entity2 . A prospective randomized trial is required to evaluate the effects of reinforcing sutures in preventing @entity2 .

title: Efficacy of intracorporeal reinforcing sutures for @entity2 after laparoscopic surgery for XXXX .

answer: @entity1


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity0 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity7 agonist ( @entity5 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity2 ( @entity2 ) @entity0 , with postoperative @entity5 -a treatment. METHODS: Ninety @entity2 @entity1 @entity0 with postoperative @entity5 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity8 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity5 -a injection, while @entity8 2.5 mg qd, po for 12 weeks in @entity8 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity4 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity8 groups was recorded. RESULTS: (1) Before @entity5 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity5 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity5 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity8 group (P < 0.05); at the 8 th and 12 th week after @entity5 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity8 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity3 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity8 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity6 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity5 -a administration to @entity2 @entity0 , although its clinical effect might be a few weeks later than @entity8 . Kuntai capsule might be a little safer than @entity8 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of XXXX Agonist Administration to Endometriosis @entity0 : A Randomized, Double-blind, Blank- and @entity8 -controlled Study.

answer: @entity7


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity0 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity7 agonist ( @entity5 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity2 ( @entity2 ) @entity0 , with postoperative @entity5 -a treatment. METHODS: Ninety @entity2 @entity1 @entity0 with postoperative @entity5 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity8 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity5 -a injection, while @entity8 2.5 mg qd, po for 12 weeks in @entity8 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity4 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity8 groups was recorded. RESULTS: (1) Before @entity5 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity5 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity5 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity8 group (P < 0.05); at the 8 th and 12 th week after @entity5 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity8 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity3 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity8 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity6 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity5 -a administration to @entity2 @entity0 , although its clinical effect might be a few weeks later than @entity8 . Kuntai capsule might be a little safer than @entity8 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of @entity7 Agonist Administration to Endometriosis @entity0 : A Randomized, Double-blind, Blank- and XXXX -controlled Study.

answer: @entity8


abstract: BACKGROUND: As a Chinese Traditional Medicine product, Kuntai capsule could improve the peri-menopausal symptoms in postmenopausal @entity0 . But it is still not clear whether Kuntai capsule has a good effect on alleviating peri-menopausal symptoms induced by @entity7 agonist ( @entity5 -a) treatment. The purpose of this study was to investigate the clinical effectiveness and safety of Kuntai capsule, on peri-menopausal symptoms in @entity2 ( @entity2 ) @entity0 , with postoperative @entity5 -a treatment. METHODS: Ninety @entity2 @entity1 @entity0 with postoperative @entity5 -a administration were enrolled in the study, and were randomly divided into Kuntai group, @entity8 group, or blank Control group. The therapeutic strategy in Kuntai group was 4 Kuntai capsules tid,po for 12 weeks after the first @entity5 -a injection, while @entity8 2.5 mg qd, po for 12 weeks in @entity8 group. There was no drug addition in Control group. Climacteric complaints were evaluated by Kupperman menopausal index (KMI) and hot flash/sweating score. @entity4 , lipid profile, serum sex hormone levels and endometrial thickness were measured, and the frequency of adverse events in Kuntai and @entity8 groups was recorded. RESULTS: (1) Before @entity5 -a therapy, the baseline parameter results were comparable in the three groups (P > 0.05). (2) After @entity5 -a therapy, KMI and hot flash/sweating scores in all the three groups increased significantly (P < 0.05). At the 4 th week after @entity5 -a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > @entity8 group (P < 0.05); at the 8 th and 12 th week after @entity5 -a therapy, KMI and hot flash/sweating score in Control group were significantly higher than the other two groups (P < 0.05), and no significant difference was identified between Kuntai and @entity8 group (P > 0.05). (3) No statistical change took place in the liver and renal functions and lipid profile in all the three groups after the treatment (P > 0.05). (4) The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and @entity3 (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05). After therapy, serum E2 level in @entity8 group was obviously higher than the other two groups (P < 0.05), while FSH and LH levels were obviously lower (P < 0.05). (5) The incidence of @entity6 , breast distending pain in Tibolne group was obviously higher than Kuntai group (P < 0. 05). CONCLUSIONS: Kuntai capsule is effective on the peri-menopausal symptoms induced by postoperative @entity5 -a administration to @entity2 @entity0 , although its clinical effect might be a few weeks later than @entity8 . Kuntai capsule might be a little safer than @entity8 tablet.

title: Efficacy and Safety Investigation of Kuntai Capsule for the Add-back Therapy of @entity7 Agonist Administration to Endometriosis XXXX : A Randomized, Double-blind, Blank- and @entity8 -controlled Study.

answer: @entity0


abstract: BACKGROUND: In China, @entity8 ( @entity8 ) aspiration, a major cause of emergency episode and @entity3 in @entity0 , remains a challenge for anesthetic management. Here, we share our experience and discuss the anesthetic consideration and management of @entity0 with @entity8 aspiration. METHODS: This was a single-institution retrospective study in @entity0 with an inhaled foreign body between 1991 and 2010 that focused on the complications following @entity7 ( @entity7 ). Data including the clinical characteristics of @entity0 and @entity8 , anesthetic method, and postoperative severe complications were analyzed by different periods. RESULTS: During the 20-year study period, the charts of 3149 @entity0 who underwent @entity7 for suspected inhaled @entity8 were reviewed. There were 2079 male and 1070 female @entity0 (1.94:1). A nut (84%) was the most commonly inhaled object. The study revealed a 9% (n = 284) overall rate of severe @entity4 related to severe @entity5 , @entity1 , complete @entity9 , pneumothorax, @entity6 , and death with incidences of 3.2%, 0.9%, 1.3%, 0.3%, 0.3%, and 0.1%, respectively. The rates of preoperative @entity2 , negative findings of @entity8 , and adverse postoperative events have been on the rise in the past 5 years. CONCLUSIONS: The survey results confirmed that @entity5 remains the most common @entity4 in different periods. Both controlled ventilation and spontaneous ventilation were effective during the @entity7 extraction of the foreign body at our hospital in the modern technique period. An active respiratory symptom was commonly seen in the groups with negative findings.

title: A time series observation of chinese @entity0 undergoing XXXX for an inhaled foreign body: 3149 cases in 1991-2010.

answer: @entity7


abstract: BACKGROUND: In China, @entity8 ( @entity8 ) aspiration, a major cause of emergency episode and @entity3 in @entity0 , remains a challenge for anesthetic management. Here, we share our experience and discuss the anesthetic consideration and management of @entity0 with @entity8 aspiration. METHODS: This was a single-institution retrospective study in @entity0 with an inhaled foreign body between 1991 and 2010 that focused on the complications following @entity7 ( @entity7 ). Data including the clinical characteristics of @entity0 and @entity8 , anesthetic method, and postoperative severe complications were analyzed by different periods. RESULTS: During the 20-year study period, the charts of 3149 @entity0 who underwent @entity7 for suspected inhaled @entity8 were reviewed. There were 2079 male and 1070 female @entity0 (1.94:1). A nut (84%) was the most commonly inhaled object. The study revealed a 9% (n = 284) overall rate of severe @entity4 related to severe @entity5 , @entity1 , complete @entity9 , pneumothorax, @entity6 , and death with incidences of 3.2%, 0.9%, 1.3%, 0.3%, 0.3%, and 0.1%, respectively. The rates of preoperative @entity2 , negative findings of @entity8 , and adverse postoperative events have been on the rise in the past 5 years. CONCLUSIONS: The survey results confirmed that @entity5 remains the most common @entity4 in different periods. Both controlled ventilation and spontaneous ventilation were effective during the @entity7 extraction of the foreign body at our hospital in the modern technique period. An active respiratory symptom was commonly seen in the groups with negative findings.

title: A time series observation of chinese XXXX undergoing @entity7 for an inhaled foreign body: 3149 cases in 1991-2010.

answer: @entity0


abstract: UNASSIGNED: Sequential use of endocrine agents is common in @entity2 ( @entity2 )-positive @entity0 ( @entity0 ). In premenopausal @entity1 with @entity0 , tamoxifen and/or a luteinizing hormone-releasing hormone (LH-RH) agonist are options for endocrine treatment. Meta-analysis showed that the combination of the two agents is superior to either monotherapy. Under ovarian ablation or function-suppression, an agent used to treat postmenopausal @entity1 , such as the @entity3 ( @entity3 ), fulvestrant, becomes possible as a subsequent therapy. In postmenopausal @entity1 , endocrine treatment options are widely available and an optimal sequence has not yet to be determined. Options for first-line therapy of metastatic disease include an @entity3 for @entity1 who have received adjuvant tamoxifen, or tamoxifen for @entity1 who have received adjuvant @entity3 . In addition, data suggest that fulvestrant is a promising therapeutic option that has proven efficacy in the treatment of postmenopausal @entity1 with @entity0 . Other agents that may be used in the sequence include a steroidal @entity3 or a progestin. Furthermore, estrogen additive therapy by with diethylstilbestrol or ethinylestradiol has recently been revived and showed a high response rate as a salvage endocrine therapy, although its mechanism of action is still unclear. Thus, sequential use of endocrine therapies, especially the use of a subsequent therapy with a different mechanism of action to the prior therapy, has a beneficial effect in maintaining a good quality of life and extending survival for @entity0 with hormone responsiveness.

title: Clinical benefit of sequential use of endocrine therapies for XXXX .

answer: @entity0


abstract: @entity1 ( @entity1 ) is a progressive disease that, if left untreated, eventually leads to @entity4 and @entity3 . @entity6 (PAP) in @entity0 with @entity1 is mainly caused by an increase in pulmonary vascular resistance (PVR). Sustained vasoconstriction and excessive @entity5 are two major causes for elevated PVR in @entity0 with @entity1 . @entity5 is mediated by increased proliferation of pulmonary arterial smooth muscle cells (PASMC) due to PASMC dedifferentiation from a contractile or quiescent phenotype to a proliferative or synthetic phenotype. Increased cytosolic @entity2 concentration ([ @entity2 ]cyt) in PASMC is a key stimulus for cell proliferation and this phenotypic transition. Voltage-dependent @entity2 entry (VDCE) and store-operated @entity2 entry (SOCE) are important mechanisms for controlling [ @entity2 ]cyt. Stromal interacting molecule proteins (e.g., @entity7 ) and @entity8 both contribute to SOCE and we have previously shown that @entity7 and @entity8 , specifically, are upregulated in PASMC from @entity0 with idiopathic @entity1 and from animals with @entity1 in comparison to normal controls. In this study, we show that @entity7 and @entity8 are upregulated in proliferating PASMC compared with contractile phenotype of PASMC. Additionally, a switch in @entity2 regulation is observed in correlation with a phenotypic transition from contractile PASMC to proliferative PASMC. PASMC in a contractile phenotype or state have increased VDCE, while in the proliferative phenotype or state PASMC have increased SOCE. The data from this study indicate that upregulation of @entity7 and @entity8 is involved in the phenotypic transition of PASMC from a contractile state to a proliferative state; the enhanced SOCE due to upregulation of @entity7 and @entity8 plays an important role in PASMC proliferation.

title: Upregulated expression of XXXX , TRPC6, and @entity8 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

answer: @entity7


abstract: @entity1 ( @entity1 ) is a progressive disease that, if left untreated, eventually leads to @entity4 and @entity3 . @entity6 (PAP) in @entity0 with @entity1 is mainly caused by an increase in pulmonary vascular resistance (PVR). Sustained vasoconstriction and excessive @entity5 are two major causes for elevated PVR in @entity0 with @entity1 . @entity5 is mediated by increased proliferation of pulmonary arterial smooth muscle cells (PASMC) due to PASMC dedifferentiation from a contractile or quiescent phenotype to a proliferative or synthetic phenotype. Increased cytosolic @entity2 concentration ([ @entity2 ]cyt) in PASMC is a key stimulus for cell proliferation and this phenotypic transition. Voltage-dependent @entity2 entry (VDCE) and store-operated @entity2 entry (SOCE) are important mechanisms for controlling [ @entity2 ]cyt. Stromal interacting molecule proteins (e.g., @entity7 ) and @entity8 both contribute to SOCE and we have previously shown that @entity7 and @entity8 , specifically, are upregulated in PASMC from @entity0 with idiopathic @entity1 and from animals with @entity1 in comparison to normal controls. In this study, we show that @entity7 and @entity8 are upregulated in proliferating PASMC compared with contractile phenotype of PASMC. Additionally, a switch in @entity2 regulation is observed in correlation with a phenotypic transition from contractile PASMC to proliferative PASMC. PASMC in a contractile phenotype or state have increased VDCE, while in the proliferative phenotype or state PASMC have increased SOCE. The data from this study indicate that upregulation of @entity7 and @entity8 is involved in the phenotypic transition of PASMC from a contractile state to a proliferative state; the enhanced SOCE due to upregulation of @entity7 and @entity8 plays an important role in PASMC proliferation.

title: Upregulated expression of @entity7 , TRPC6, and XXXX contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype.

answer: @entity8


abstract: Xyloglucan is a polysaccharide that has important roles in the formation and function of the walls that surround growing land plant cells. Many of these plants synthesize xyloglucan that contains @entity1 in two different side chains (L and F), which exist in distinct molecular environments. However, little is known about the contribution of these side chains to xyloglucan function. Here, we show that @entity0 ( @entity0 ) mutants devoid of the F side chain galactosyltransferase @entity2 ( @entity2 ) form xyloglucan that lacks F side chains and contains much less galactosylated xylose than its wild-type counterpart. The @entity1 -depleted xyloglucan is dysfunctional, as it leads to mutants that are dwarfed with curled rosette leaves, short petioles, and short inflorescence stems. Moreover, cell wall matrix polysaccharides, including xyloglucan and pectin, are not properly secreted and instead accumulate within intracellular aggregates. Near-normal growth is restored by generating @entity2 mutants that produce no detectable amounts of xyloglucan. Thus, cellular processes are affected more by the presence of the dysfunctional xyloglucan than by eliminating xyloglucan altogether. To identify structural features responsible for xyloglucan dysfunction, xyloglucan structure was modified in situ by generating @entity2 mutants that lack specific xyloglucan xylosyltransferases (XXTs) or that overexpress the XYLOGLUCAN L-SIDE CHAIN GALACTOSYLTRANSFERASE2 (XLT2) gene. Normal growth was restored in the @entity2 -3 mutant overexpressing XLT2 and in @entity2 -3 xxt double mutants when the dysfunctional xyloglucan was modified by doubling the amounts of galactosylated side chains. Our study assigns a role for galactosylation in normal xyloglucan function and demonstrates that altering xyloglucan side chain structure disturbs diverse cellular and physiological processes.

title: XXXX -depleted xyloglucan is dysfunctional and leads to dwarfism in @entity0 .

answer: @entity1


abstract: Xyloglucan is a polysaccharide that has important roles in the formation and function of the walls that surround growing land plant cells. Many of these plants synthesize xyloglucan that contains @entity1 in two different side chains (L and F), which exist in distinct molecular environments. However, little is known about the contribution of these side chains to xyloglucan function. Here, we show that @entity0 ( @entity0 ) mutants devoid of the F side chain galactosyltransferase @entity2 ( @entity2 ) form xyloglucan that lacks F side chains and contains much less galactosylated xylose than its wild-type counterpart. The @entity1 -depleted xyloglucan is dysfunctional, as it leads to mutants that are dwarfed with curled rosette leaves, short petioles, and short inflorescence stems. Moreover, cell wall matrix polysaccharides, including xyloglucan and pectin, are not properly secreted and instead accumulate within intracellular aggregates. Near-normal growth is restored by generating @entity2 mutants that produce no detectable amounts of xyloglucan. Thus, cellular processes are affected more by the presence of the dysfunctional xyloglucan than by eliminating xyloglucan altogether. To identify structural features responsible for xyloglucan dysfunction, xyloglucan structure was modified in situ by generating @entity2 mutants that lack specific xyloglucan xylosyltransferases (XXTs) or that overexpress the XYLOGLUCAN L-SIDE CHAIN GALACTOSYLTRANSFERASE2 (XLT2) gene. Normal growth was restored in the @entity2 -3 mutant overexpressing XLT2 and in @entity2 -3 xxt double mutants when the dysfunctional xyloglucan was modified by doubling the amounts of galactosylated side chains. Our study assigns a role for galactosylation in normal xyloglucan function and demonstrates that altering xyloglucan side chain structure disturbs diverse cellular and physiological processes.

title: @entity1 -depleted xyloglucan is dysfunctional and leads to dwarfism in XXXX .

answer: @entity0


abstract: UNASSIGNED: Primary oral mucosal @entity3 (POMM) is uncommon. Its biological behavior is more aggressive than that of @entity3 . Its site-specific prognostic factors and optimal management have not been determined yet. Retrospective POMM case analysis from peer-reviewed publications in the PubMed and Embase electronic database from January 1984 to December 2013, in which therapy and outcome data were available, was performed. A total of 151 primary cases were extracted from 39 peer-reviewed English literatures. The study population includes 63 males and 88 females with a medium age of 61 years. The treatment protocols include surgery alone (18%), radiotherapy alone (14%), surgery plus radiotherapy (14%), surgery plus chemotherapy (31%), as well as surgery plus chemoradiotherapy (15%) and chemoradiotherapy (8%). The male @entity0 have a higher risk for @entity1 than the female @entity0 do (odds ratio [OR]; 3.41, P = 0.021). The POMM originating from specialized mucosa was associated with increased risk for @entity2 recurrence and mortality (OR, 4.03, P = 0.001; OR, 2.03, P = 0.031, respectively). The @entity0 who had surgery-based multiple therapy have a significantly longer survival compared with those who had surgery alone and those who had no surgical treatment (P = 0.000). The age of 60 years or younger (hazard ratio [HR], 4.69; P = 0.000), nonsurgical treatment (HR, 12.838; P = 0.000), and surgery alone (HR, 1.517; P = 0.001) were independent adverse prognostic factors for overall survival. Taken together, the study results suggest that surgery-based multiple therapy is the most effective treatment protocol. The age of 60 years, nonsurgical treatment, and surgery alone were independent adverse prognostic factors for overall survival.

title: The Management and Site-Specific Prognostic Factors of Primary Oral Mucosal XXXX .

answer: @entity3


abstract: UNASSIGNED: Although @entity0 diagnosed during pregnancy is rare, @entity1 (EOCs) comprise approximately one quarter to one half of cases of @entity1 diagnosed during pregnancy. The behavior of EOC during pregnancy and its implications for maternal and fetal outcomes is not well understood. In order to better define these outcomes, a systematic literature search was conducted in PubMed/MEDLINE using @entity1 " for the period from 1955 to 2013. The literature search identified 105 cases eligible for analysis. Clinical characteristics, pregnancy outcome, @entity0 characteristics, clinical management, and survival outcomes were all evaluated. Serious adverse events were defined as complications related to EOC that resulted in severe morbidity or mortality for the mother and/or fetus. The mean age of cases was 31.6 years. The most common histology was serous (47.6%), followed by mucinous (27.6%) and endometrioid types (10.5%). The most common presenting symptom was abdominal or pelvic @entity2 (26.7%) while incidentally detected @entity0 accounted for one third of cases. The majority of cases were stage I at diagnosis (63.8%) followed by @entity0 (24.8%), and the median @entity0 size was 12cm. Live births occurred in 81.3% of cases, and of the remainder 72.2% were due to elective termination. Intrapartum surgery primarily took place in the second trimester (43%) with fetal conservation in 61.9% of operations. Over half of cases received chemotherapy (55.2%), approximately one third of which received it during the pregnancy (36.2%). Among the 21 cases treated with chemotherapy during pregnancy, there was no association with small for gestational age or fetal malformations. Serious adverse events occurred in 21.9% of cases, of which the most common was @entity0 rupture during pregnancy (10.5%). Three (2.9%) maternal @entity3 following surgery during pregnancy and five (6.4%) neonatal @entity3 were reported. Gestational age at @entity0 diagnosis (2-year overall survival rate, 1st trimester 94.6%, 2nd trimester 88.8%, and 3rd trimester 72.9%, p=0.041) type of histology (serous 88.1%, mucinous 84.6%, endometrioid 89.5%, clear cell 100%, mixed type 75.0%, and undifferentiated 30.0%, p<0.01), stage (stage I 96.9%, stage II 85.7%, stage III 56.3%, and stage IV 25.0%, p<0.01), and serious adverse events (yes versus no, 68.1% versus 92.2%, p=0.041) were significantly related to maternal overall survival in univariate analysis. In multivariate analysis, stage III/IV disease remained the independent prognostic factor associated with decreased maternal overall survival (stage III, hazard ratio 44.6, p<0.01; and stage IV, hazard ratio 399, p<0.01). In conclusion, although the majority of EOC cases during pregnancy resulted in live birth, maternal and neonatal mortality needs to be considered in the counseling and management of these pregnancies.

title: Feto-maternal outcomes of pregnancy complicated by XXXX : a systematic review of literature.

answer: @entity1


abstract: UNASSIGNED: Background. @entity5 , common in general medical practice, is under-recognized and inadequately managed resulting in significant morbidity and reduction in quality of life. We examined the nature, prevalence, clinical features and explanatory models of @entity4 among @entity0 with @entity5 in a general healthcare setting. Methods. We recruited 270 consecutive @entity0 attending a general health clinic. @entity0 were evaluated using a structured interview. The International Index of Erectile Function-5, the Chinese Index of Premature Ejaculation-5, Short Explanatory Model Interview and the Revised Clinical Interview Schedule were used to assess @entity5 , explanatory models and @entity2 morbidity. Results. @entity8 and @entity7 were reported by 43.0% and 47.8% of @entity0 , respectively. The most common perceived causes were loss of semen due to masturbation and nocturnal emission. Popular treatments were herbal remedies and resources used were traditional healers. The factors associated with @entity7 were @entity1 , financial stress, past history of @entity2 treatment and @entity2 such as @entity6 and @entity3 ; those associated with @entity8 were @entity2 , older age and financial debt. @entity5 and concerns were under-diagnosed by physicians when compared to the research interview. Conclusion. There is a need to recognize sexual problems and effectively manage them in general medical settings. The need for sex education in schools and through the mass media, to remove sexual misconceptions, cannot be under-emphasized.

title: XXXX among @entity0 in secondary care in southern India: Nature, prevalence, clinical features and explanatory models.

answer: @entity5


abstract: UNASSIGNED: Background. @entity5 , common in general medical practice, is under-recognized and inadequately managed resulting in significant morbidity and reduction in quality of life. We examined the nature, prevalence, clinical features and explanatory models of @entity4 among @entity0 with @entity5 in a general healthcare setting. Methods. We recruited 270 consecutive @entity0 attending a general health clinic. @entity0 were evaluated using a structured interview. The International Index of Erectile Function-5, the Chinese Index of Premature Ejaculation-5, Short Explanatory Model Interview and the Revised Clinical Interview Schedule were used to assess @entity5 , explanatory models and @entity2 morbidity. Results. @entity8 and @entity7 were reported by 43.0% and 47.8% of @entity0 , respectively. The most common perceived causes were loss of semen due to masturbation and nocturnal emission. Popular treatments were herbal remedies and resources used were traditional healers. The factors associated with @entity7 were @entity1 , financial stress, past history of @entity2 treatment and @entity2 such as @entity6 and @entity3 ; those associated with @entity8 were @entity2 , older age and financial debt. @entity5 and concerns were under-diagnosed by physicians when compared to the research interview. Conclusion. There is a need to recognize sexual problems and effectively manage them in general medical settings. The need for sex education in schools and through the mass media, to remove sexual misconceptions, cannot be under-emphasized.

title: @entity5 among XXXX in secondary care in southern India: Nature, prevalence, clinical features and explanatory models.

answer: @entity0


abstract: BACKGROUND: The association between hospital teaching status and mortality after pancreatic resection is not well explored. Although hospital volume is related to short-term mortality, the effect on long-term survival needs investigation, taking into account hospital teaching status and selective referral patterns. METHODS: This was a nationwide retrospective register-based cohort study of @entity0 undergoing pancreatic resection between 1990 and 2010. Follow-up for survival was carried out until 31 December 2011. The associations between hospital teaching status and annual hospital volume and short-, intermediate- and long-term mortality were determined by use of multivariable Cox regression models, which provided hazard ratios (HRs) with 95 per cent c.i. The analyses were mutually adjusted for hospital teaching status and volume, as well as for @entity0 ' sex, age, education, co-morbidity, type of resection, @entity1 site and histology, time interval, referral and hospital clustering. RESULTS: A total of 3298 @entity0 were identified during the study interval. Hospital teaching status was associated with a decrease in overall mortality during the latest interval (years 2005-2010) (university versus non-university hospitals: HR 0  72, 95 per cent c.i. 0  56 to 0  91; P   =   0  007). During all time periods, hospital teaching status was associated with decreased mortality more than 2   years after surgery (university versus non-university hospitals: HR 0  86, 0  75 to 0  98; P   =   0  026). Lower annual hospital volume increased the risk of short-term mortality (HR for 3 or fewer compared with 4-6 @entity2 resections annually: 1  60, 1  04 to 2  48; P   =   0  034), but not long-term mortality. Sensitivity analyses with adjustment for @entity1 stage did not change the results. CONCLUSION: Hospital teaching status was strongly related to decreased mortality in both the short and long term. This may relate to processes of care rather than volume per se. Very low-volume hospitals had the highest short-term mortality risk.

title: Hospital teaching status and volume related to mortality after XXXX surgery in a national cohort.

answer: @entity2


abstract: UNASSIGNED: The objectives of the study were  to determine the relative importance of barriers related to the provision of intensive combination treatment strategies with glucocorticoids (ICTS-GCs) in early @entity1 (ERA) from the rheumatologists' perspective and to explore the relation between rheumatologists' characteristics and importance scores. A @entity2 ( @entity2 ) survey was administered to 66 rheumatologists in Flanders and the Brussels-Capital Region. The survey included 25 barriers, previously being discovered in a qualitative study. The survey included 25 choice sets, each of which contained a different set of four barriers. In each choice situation, respondents were asked to choose the most important barrier. The mean relative importance score (RIS) for each barrier was calculated using hierarchical Bayes modeling. The potential relation between rheumatologists' characteristics and the RIS was examined using Spearman's correlation coefficient, Mann-Whitney U test, and Kruskal-Wallis H test. The three highest ranked barriers included "contraindicated for some @entity0 (e.g., @entity0 with comorbidities, older @entity0 )," "an increased risk of side effects and related complications," and " @entity0 ' resistance" with a mean        SD RIS of 9.76        0.82, 8.50        1.17, and 7.45        1.22, respectively. Comparing the RISs based on rheumatologists' characteristics, a different ranking was found for three barriers depending on the age, university location, and/or frequency of prescribing ICTS-GCs. The dominant barriers hindering ICTS-GCs prescription from a rheumatologists' perspective are @entity0 -related barriers and barriers related to the complexity of prescribing a combination therapy including GCs. A tailored improvement intervention is needed to overcome these barriers and should focus on the familiarity of rheumatologists with ICTS-GC and @entity0 education.

title: A XXXX survey of barriers to intensive combination treatment strategies with glucocorticoids in early @entity1 .

answer: @entity2


abstract: UNASSIGNED: The objectives of the study were  to determine the relative importance of barriers related to the provision of intensive combination treatment strategies with glucocorticoids (ICTS-GCs) in early @entity1 (ERA) from the rheumatologists' perspective and to explore the relation between rheumatologists' characteristics and importance scores. A @entity2 ( @entity2 ) survey was administered to 66 rheumatologists in Flanders and the Brussels-Capital Region. The survey included 25 barriers, previously being discovered in a qualitative study. The survey included 25 choice sets, each of which contained a different set of four barriers. In each choice situation, respondents were asked to choose the most important barrier. The mean relative importance score (RIS) for each barrier was calculated using hierarchical Bayes modeling. The potential relation between rheumatologists' characteristics and the RIS was examined using Spearman's correlation coefficient, Mann-Whitney U test, and Kruskal-Wallis H test. The three highest ranked barriers included "contraindicated for some @entity0 (e.g., @entity0 with comorbidities, older @entity0 )," "an increased risk of side effects and related complications," and " @entity0 ' resistance" with a mean        SD RIS of 9.76        0.82, 8.50        1.17, and 7.45        1.22, respectively. Comparing the RISs based on rheumatologists' characteristics, a different ranking was found for three barriers depending on the age, university location, and/or frequency of prescribing ICTS-GCs. The dominant barriers hindering ICTS-GCs prescription from a rheumatologists' perspective are @entity0 -related barriers and barriers related to the complexity of prescribing a combination therapy including GCs. A tailored improvement intervention is needed to overcome these barriers and should focus on the familiarity of rheumatologists with ICTS-GC and @entity0 education.

title: A @entity2 survey of barriers to intensive combination treatment strategies with glucocorticoids in early XXXX .

answer: @entity1


abstract: @entity4 mediated by activation of hepatic stellate cells (HSCs) leads to liver @entity3 . Here, we postulated that the immune regulatory properties of HSCs might promote the profibrogenic activity of B cells. @entity3 is completely attenuated in @entity8 -treated, B cell-deficient   MT @entity1 , showing that B cells are required. The @entity6 produced by HSCs augmented B-cell survival, plasma cell marker @entity9 expression, and immunoglobulin G production. These activities were reversed following addition of the @entity6 inhibitor @entity14 . Transcriptional profiling of fibrotic liver B cells revealed increased expression of genes related to activation of nuclear factor k light chain enhancer of activated B cells, proinflammatory cytokine production, and @entity12 signaling, suggesting that these B cells are activated and may be acting as inflammatory cells. Biological validation experiments also revealed increased activation ( @entity7 and @entity10 expression), constitutive immunoglobulin G production, and secretion of the proinflammatory cytokines @entity0 @entity2 factor-a, @entity5 , and macrophage inflammatory protein-1a. Likewise, targeted deletion of B-cell-intrinsic myeloid differentiation primary response gene 88 signaling, an innate adaptor with involvement in @entity6 signaling, resulted in reduced infiltration of migratory @entity11 (+) dendritic cells and @entity13 (++) monocytes and, hence, reduced liver pathology. CONCLUSION: Liver @entity3 occurs through a mechanism of HSC-mediated augmentation of innate B-cell activity. These findings highlight B cells as important "first responders" of the intrahepatic immune environment.

title: Liver XXXX occurs through dysregulation of MyD88-dependent innate B-cell activity.

answer: @entity3


abstract: UNASSIGNED: The aim of this systematic review was to identify and describe brief dietary assessment tools suitable for use in clinical practice in the management of @entity2 , @entity3 and @entity4 2 @entity1 . Papers describing development of brief (<35 items) dietary assessment questionnaires, that were accessible, simple to score and assessed aspects of the diet of relevance to the conditions of interest were identified from electronic databases. The development of 35 tools was described in 47 papers. Ten tools assessed healthy eating or healthy dietary patterns, 2 assessed adherence to the Mediterranean diet, 18 assessed dietary fat intake, and 5 assessed vegetable and/or fruit intake. Twenty tools were developed in North America. Test-retest reliability was conducted on 18 tools; correlation coefficients for total scores ranged from 0.59 to 0.95. Relative validation was conducted on 34 tools. The most common reference variable was percentage energy from fat (15 tools) and correlation coefficients ranged from 0.24, P<0.001 to 0.79, P<0.002. Tools that have been evaluated for reliability and/or relative validity are suitable for guiding clinicians when providing dietary advice. Variation in study design, settings and populations makes it difficult to recommend one tool over another, although future developers can enhance the understanding and use of tools by giving clear guidance as to the strengths and limitations of the study design. When selecting a tool, clinicians should consider whether their @entity0 population is similar in characteristics to the evaluation sample.European Journal of Clinical Nutrition advance online publication, 25 February 2015; doi:10.1038/ejcn.2015.6.

title: A systematic review of brief dietary questionnaires suitable for clinical use in the prevention and management of @entity2 , @entity3 and XXXX 2 @entity1 .

answer: @entity4


abstract: UNASSIGNED: The aim of this systematic review was to identify and describe brief dietary assessment tools suitable for use in clinical practice in the management of @entity2 , @entity3 and @entity4 2 @entity1 . Papers describing development of brief (<35 items) dietary assessment questionnaires, that were accessible, simple to score and assessed aspects of the diet of relevance to the conditions of interest were identified from electronic databases. The development of 35 tools was described in 47 papers. Ten tools assessed healthy eating or healthy dietary patterns, 2 assessed adherence to the Mediterranean diet, 18 assessed dietary fat intake, and 5 assessed vegetable and/or fruit intake. Twenty tools were developed in North America. Test-retest reliability was conducted on 18 tools; correlation coefficients for total scores ranged from 0.59 to 0.95. Relative validation was conducted on 34 tools. The most common reference variable was percentage energy from fat (15 tools) and correlation coefficients ranged from 0.24, P<0.001 to 0.79, P<0.002. Tools that have been evaluated for reliability and/or relative validity are suitable for guiding clinicians when providing dietary advice. Variation in study design, settings and populations makes it difficult to recommend one tool over another, although future developers can enhance the understanding and use of tools by giving clear guidance as to the strengths and limitations of the study design. When selecting a tool, clinicians should consider whether their @entity0 population is similar in characteristics to the evaluation sample.European Journal of Clinical Nutrition advance online publication, 25 February 2015; doi:10.1038/ejcn.2015.6.

title: A systematic review of brief dietary questionnaires suitable for clinical use in the prevention and management of XXXX , @entity3 and @entity4 2 @entity1 .

answer: @entity2


abstract: UNASSIGNED: The aim of this systematic review was to identify and describe brief dietary assessment tools suitable for use in clinical practice in the management of @entity2 , @entity3 and @entity4 2 @entity1 . Papers describing development of brief (<35 items) dietary assessment questionnaires, that were accessible, simple to score and assessed aspects of the diet of relevance to the conditions of interest were identified from electronic databases. The development of 35 tools was described in 47 papers. Ten tools assessed healthy eating or healthy dietary patterns, 2 assessed adherence to the Mediterranean diet, 18 assessed dietary fat intake, and 5 assessed vegetable and/or fruit intake. Twenty tools were developed in North America. Test-retest reliability was conducted on 18 tools; correlation coefficients for total scores ranged from 0.59 to 0.95. Relative validation was conducted on 34 tools. The most common reference variable was percentage energy from fat (15 tools) and correlation coefficients ranged from 0.24, P<0.001 to 0.79, P<0.002. Tools that have been evaluated for reliability and/or relative validity are suitable for guiding clinicians when providing dietary advice. Variation in study design, settings and populations makes it difficult to recommend one tool over another, although future developers can enhance the understanding and use of tools by giving clear guidance as to the strengths and limitations of the study design. When selecting a tool, clinicians should consider whether their @entity0 population is similar in characteristics to the evaluation sample.European Journal of Clinical Nutrition advance online publication, 25 February 2015; doi:10.1038/ejcn.2015.6.

title: A systematic review of brief dietary questionnaires suitable for clinical use in the prevention and management of @entity2 , XXXX and @entity4 2 @entity1 .

answer: @entity3